We are delighted to announce our current grant awardees, spanning the fields of Birt-Hogg-Dubé Syndrome (BHD) and osteosarcoma.
The Myrovlytis Trust re-established grant giving activity in 2021, with the first round of funding decided upon by our grant review panel following rigorous peer review. We have funded BHD projects looking at the prevalence of BHD using large-scale genomic databases, a study to identify new or linked manifestations of BHD, and a detailed single-cell analysis of the tumour microenvironment for the skin manifestation.
In the osteosarcoma field, we have funded a pre-clinical study to assess the activity of a humanised antibody against sFRP2 in combination with other therapies for the treatment of metastatic disease, and a study looking at the role of oncolytic virus-based activation of Natural Killer cells for treatment of osteosarcoma.
Communicating the science
An important component of all research we fund will be the communication of these projects to various audiences. We intend to provide plenty of opportunites for researchers to engage with the rare disease community, the public and other researchers. We have recently funded a science communication course for PhD students in BHD and osteosarcoma to equip the next generation with the necessary tools to be excellent communicators and ambassadors.
Meet our grant awardees
The lead investigators have produced a lay summary and a video to introduce their research projects, listed below. Please take some time to hear about the interesting avenues and potential impact of these studies by following the links below.
Learn more about Arjan’s research project here.